Can probiotics cure inflammatory bowel diseases?

Current Pharmaceutical Design

Volumn 22, Issue 7, 2016, Pages 904-917

  Korada, Siva Kumar ^a   Yarla, Nagendra Sastry ^b   Bishayee, Anupam ^c   Aliev, Gjumrakch ^d,e,f   Aruna, Lakshmi K ^b   Arunasree, M K ^g,h   Dhananjaya, B L ⁱ   Mishra, Vijendra ^a  

^a NATIONAL INSTITUTE OF FOOD TECHNOLOGY ENTREPRENEURSHIP AND MANAGEMENT   (India)

^b GITAM UNIVERSITY   (India)

^c Larkin Health Science Institute   (United States)

^d GALLY International Biomedical Research Institute Inc   (United States)

^e University of Atlanta   (United States)

^f INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

^g UNIVERSITY OF HYDERABAD   (India)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ JAIN UNIVERSITY   (India)

Author keywords

Gastrointestinal disorder; Inflammatory bowel diseases; Microbial dysbiosis; Probiotics; Ulcerative colitis

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; FOLIC ACID ANTAGONIST; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIBIOTIC THERAPY; ARTICLE; CAMPYLOBACTER; CELL THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; COMMENSAL; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DISEASE CONTROL; DRUG MECHANISM; EPSTEIN BARR VIRUS INFECTION; ESCHERICHIA COLI; HEALTH STATUS; HELICOBACTER PYLORI; HUMAN; HUMAN PARVOVIRUS B19; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; LISTERIA MONOCYTOGENES; METABOLISM; MYCOBACTERIUM AVIUM; NOROVIRUS INFECTION; PARAMYXOVIRUS INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; SALMONELLA; STOMACH PROTECTION; TREATMENT INDICATION; ULCERATIVE COLITIS; ANIMAL; DIARRHEA; GASTROINTESTINAL DISEASES; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; MICROBIOLOGY; PATHOPHYSIOLOGY;

ANIMALS; DIARRHEA; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; PROBIOTICS;

EID: 84958568119     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151209153249     Document Type: Article

References (184)

1. Gemlyn G, Ramadass B. Defining human gut microbiome: role of diet and infection. Probiotics, microbiome and gut functiontransforming health and wealth. USA: Elsevier 2014; pp. 1-13, ISBN 978-81-312-4054-60.
2. Littman DR, Pamer EG. Role of the commensal microbiota in normal and pathogenic host immune responses. Cell Host Microbe 2011; 10: 311-23.
3. Honda K, Littman DR. The microbiome in infectious disease and inflammation. Ann Rev Immunol 2012; 30: 759-95.
4. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease Nature 2007; 448: 427-34.
5. Metchnikoff E. Optimistic studies. New York: Putman’s Sons 1908; pp. 161-83.
6. Colin H, Francisco G, Gregor R, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11: 506-14.
7. Shah NP. Probiotics and prebiotics. Agro-Food Ind Hi-tech 2004; 15: 13-6.
8. Vasiljevic, Shah NP. Review: probiotics — from Metchnikoff to bioactives. Int Dairy J 2008; 18: 714-28.
9. Neerja H, Balakrish NG, Ramakrishna BS, Ganguly NK. Probiotic foods: Can their increasing use in India ameliorate the burden of chronic lifestyle disorders? Indian J Med Res 2014; 139: 19-26
10. Claesson MJ, Cusack S, O’Sullivan O, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA 2011; 108: (Suppl 14): 586-91.
11. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635-8.
12. Turroni F, Foroni E, Pizzetti P, et al. Exploring the diversity of the bifidobacterial population in the human intestinal tract. Appl Environ Microbiol 2009; 75: 1534-45.
13. Lagier J, Armougom F, Million M, et al. Microbial culturomics: paradigm shift in the human gut microbiome study. Clin Microbiol Infect 2012; 18: 1185-93.
14. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006; 124: 837-48.
15. Young VB.The intestinal microbiota in health and disease. Curr Opin Gastro 2012; 28: 63-9.
16. Sun J, Chang EB. Exploring gut microbes in human health and disease: Pushing the envelope. Genes Dis 2014; 1: 132-9.
17. Salminen S, Isolauri E. Opportunities for improving the health and nutrition of the human infant by probiotics. Nestle Nutr Workshop Ser Pediatr Program 2008; 62: 223-33.
18. Caicedo RA, Schanler RJ, Li N, Neu J. The developing intestinal ecosystem: Implications for the neonate. Pediatr Res 2005; 58: 625-8.
19. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr 1999; 69: 1035S-45S.
20. Rotimi, V.O, Duerden, B.I. The development of the bacterial flora in normal neonates. J Med Microbiol 1981; 14: 51-62.
21. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006; 7(7): 688-93.
22. Bergman EN. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol Rev 1990; 70: 567-90.
23. Hooper LV, Midtvedt T, Gordon JI. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr 2002; 22: 283-307.
24. Inna S, Shannon RL, Caetano MA, Brett FB. Gut microbiota in health and disease. Physiol Rev 2010; 90: 859-904.
25. Metges CC. Contribution of microbial amino acids to amino acid homeostasis of the host. J Nutr 2000; 130: 1857S-64S.
26. Metges CC, Petzke KJ. Utilization of essential amino acids synthesized in the intestinal microbiota of monogastric mammals. Br J Nutr 2005; 94: 621-2.
27. Hill MJ: Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev 1997; 6(Suppl 1): S43-S45.
28. Heselmans M, Reid G, Akkermans LM, Savelkoul H, Timmerman H, Rombouts FM. Gut flora in health and disease: potential role of probiotics. Curr Issues Intest Microbiol 2005; 6: 1-7.
29. Ridlon JM, Kang DL, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006; 47: 241-59.
30. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 2003; 83: 633-71.
31. Momose Y, Hirayama K, Itoh K. Competition for proline between indigenous Escherichia coli and E. coli O157: H7 in gnotobiotic mice associated with infant intestinal microbiota and its contribution to the colonization resistance against E. coli O157: H7. Antonie Van Leeuwenhoek 2008; 94: 165-71.
32. Momose Y, Hirayama K, Itoh K. Effect of organic acids on inhibition of Escherichia coli O157: H7colonization in gnotobiotic mice associated with infant intestinal microbiota. Antonie Van Leeuwenhoek 2008; 93: 141-49.
33. Fabich AJ, Jones SA, Chowdhury FZ, et al. Comparison of carbon nutrition for pathogenic and commensal Escherichia coli strains in the mouse intestine. Infect Immun 2008; 76: 1143-52.
34. Mary PL, Swati B, Steven MA, Regino ML, Tyrrell C, Paul SC. Precolonized human commensal Escherichia coli strains serve as a barrier to E.coli O157: H7 growth in the streptomycin-treated mouse intestine. Infect Immun 2009; 77: 2876-86.
35. Hammami R, Fernandez B, Lacroix C, Fliss I. Anti-infective properties of bacteriocins: an update. Cell Mol Life Sci 2013; 70: 2947-67.
36. Franchi L, Kamada N, Nakamura Y, et al. NLRC4-driven production of IL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat Immunol 2012; 13: 449-56.
37. Ohland CL, Macnaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 2010; 298: G807-9.
38. Macpherson AJ, Geuking MB, Slack E, Hapfelmeier S, McCoy KD. The habitat, double life, citizenship, and forgetfulness of IgA. Immunol Rev 2012; 245: 132-46.
39. Janoff EN, Gustafson C, Frank DN. The world within: Living with our microbial guests and guides. Transl Res 2012; 160: 239-45.
40. Macpherson, AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 2004; 303: 1662-5.
41. Uematsu S, Fujimoto K, Jang MH, et al. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nature Immunol 2008; 9: 769-776.
42. Ashida H, Ogawa M, Kim M, Mimuro H, Sasakawa C. Bacteria and host interactions in the gut epithelial barrier. Nat Chem Biol 2011; 8: 36-45.
43. Sharma R, Young C, Neu J. Molecular modulation of intestinal epithelial barrier: contribution of microbiota. J Biomed Biotechnol 2010; (2010): 305-879.
44. Baumgart DC, Carding SR. Inflammatory bowel disease: cause an immunobiology. Lancet 2007; 369 (9573): 1627-40.
45. Loftus EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterol 2004; 126: 1504-17.
46. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet 1991; 338: 771-4.
47. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29.
48. Daisy J, Reinhold S. Probiotics and inflammatory bowel disease. J R Soc Med 2003; 96: 167-71.
49. Fazl QP, Mohd LW, Ajaz AM, et al. Ulcerative colitis: A Challenge to Surgeons. Int J Prev Med 2012; 3: 749-63.
50. Russel MG, Stockbrugger RW. Epidemiology of inflammatory bowel disease: an update. Scand J Gastroenterol 1996; 31: 417-27.
51. Mallon PT, McKay D, Kirk SJ, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; 4; Art. No: CD005573.
52. Wen Z, Fiocchi C. Inflammatory bowel disease: Autoimmune or immune-mediated pathogenesis?. Clin Dev Immunol 2004; 11: 195-204.
53. Crohn's Disease. National Digestive Diseases Information Clearinghouse (NDDIC). July 10, 2013 (Accessed). Available [http://www.niddk.nih.gov/health-information/health-topics/digestivediseases/crohns-disease/Pages/facts.aspx].
54. Schreiber S, Nikolaus S, Hampe J, et al. Twnour necrosis factor alpha and interleukin-lbeta in relapse of Crohn's disease. Lancet 1999; 353: 459-61.
55. Baumgart DC, Sandborn WJ; Sandborn. "Crohn's disease". Lancet 2012; 380 (9853): 1590-605.
56. Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010; 16: 90-7.
57. Mills S, Stamos MJ. Colonic Crohn’s Disease. Clin Colon Rectal Surg 2007; 20: 309-13.
58. Barbara S, Fergus S, Liam O’M. Probiotic effects on inflammatory bowel disease. J Nutr 2007; 137: 819S-24S.
59. Bamias G, Marini M, Moskaluk CA, et al. Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease. J Immunol 2002; 169: 5308-14.
60. Magalhães J, Castro FD, Carvalho PB, Moreira MJ, Cotter J. Quality of life in patients with inflammatorybowel disease: importance of clinical, demographic and psychosocial factors. Arq Gastroenterol 2014; 51: 192-7.
61. Sales-CH, Basso PJ, Alves VBF, et al. Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J Med Biol Res 2015; 48: 96-107.
62. Pineiro M, Stanton C. Probiotic bacteria: Legislative framework-requirements to evidence basis. J Nutr 2007; 137: 850.
63. Falagas ME, Rafailidis PI, Makris GC. Bacterial interference for the prevention and treatment of infections. Int J Antimicrob Agents 2008; 31: 518-22.
64. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve non-alcoholic fatty liver disease. Hepatology 2003; 37: 343-50.
65. Vijendra M, Chandni S, Narendra M, Rupesh C, Hariom Y, Jashbhai P. Probiotics as Potential Antioxidants: A Systematic Review. J Agric Food Chem 2015; 63: 3615-26.
66. Park E, Jeon GI, Park JS, Paik HD. A probiotic strain of Bacillus polyfermenticus reduces. DMH induced precancerous lesions in F344 male rat. Biol Pharm Bull 2007; 30: 569-74.
67. Zhang Y, Du R, Wang L, Zhang H. The antioxidative effects of probiotic Lactobacillus casei Zhang on the hyperlipidemic rats. Eur Food Res Tech 2010; 231: 151-8.
68. Baldwin C, Millette M, Oth D, et al. Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis. Nutr Cancer 2010; 62: 371-8.
69. Elise L. Ma, Yoon Jeong Choi, Jinyoung Choi, Charalabos Pothoulakis, Sang Hoon Rhee and Eunok Im. The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition. Int J Cancer 2010; 127: 780-90.
70. Michael de V, Anna S, Bernd R, Susanne F, Christiane L, Jürgen S. Probiotics—compensation for lactase insufficiency. Am J Clin Nutr 2001; 73: 421s-9s.
71. Homayouni A, Bastani P, Ziyadi S, et al. Effects of probiotics on the recurrence of bacterial vaginosis: a review. J Low Genit Tract Di 2014; 18: 79-86.
72. Velraeds MM, Van der Mei HC, Reid G, Busscher HJ. Inhibition of initial adhesion or uropathogenic Enterococcus faecalis by biosurfactants from Lactobacillus isolates. Appl Environ Microbiol 1996; 62: 1958-63.
73. Kumar KS, Sastry N, Polaki H, Mishra V. Colon cancer prevention through probiotics: an overview. J Cancer Sci Ther 2015; 7: 081-092.
74. Lye HS, Rusul RAG, Liong MT. Mechanisms of cholesterol removal by lactobacilli under conditions that mimic the human gastrointestinal tract. Int Dairy J 2010; 20: 169-75.
75. Bottazzi V, Zacconi C, Gonzaga E, Paladino M. Absorption of cholesterol by intestinal lactic acid bacteria. Ann Microbiol 1986; 36: 1-5.
76. Kawahara T, Takahashi T, Oishi K, et al. Consecutive oral administration of Bifidobacterium longum MM-2 improves the defense system against influenza virus infection by enhancing natural killer cell activity in a murine model. Microbiol Immunol 2015; 59: 1-12.
77. Yasui H, Kiyoshima J, Hori T, Shida K. Protection against influenza virus infection of mice fed Bifidobacterium breve YIT4064. Clin Diagn Lab Immunol 1999; 6: 186-92.
78. Weidong C, Michael B, Zhenya W, et al. Antiviral effects of a probioticEnterococcus faecium strain against transmissible gastroenteritis coronavirus. Arch Virol 2013; 158: 799-807.
79. Manish KL, Barjesh CS , Praveen S, Sanjeev S, Siddharth S. Probiotics prevent hepatic encephalopathy in patients With Cirrhosis: A randomized controlled trial. Clin Gasteroenterol Hepatol 2014; 12: 1003-8.
80. Kim JY, Choi YO, Ji GE. Effect of oral probiotics (Bifidobacterium lactis AD 011 and Lactobacillus acidophilus AD 031) administration on ovalbumin-induced food allergy mouse model. J Microbiol Biotechnol 2008; 18: 1393-1400.
81. He F, Morita H, Hashimoto H, et al. Intestinal Bifidobacterium species induce varying cytokine production. J Allergy Clin Immunol 2002; 109: 1035-6.
82. Sudhir R, Praveen P, Anantharaj A, Venkataraghavan K. Assessment of the effect of probiotic curd consumption on salivary pH and streptococcus mutanscounts. Nigerian Med J 2012; 53: 135-9.
83. Rather SA, Pothuraju R, Sharma RK, De S, Mir NA, Jangra S. Anti-obesity effect of feeding probiotic dahi containing Lactobacillus casei NCDC 19 in high fat diet-induced obese mice. Int J Dairy Tech 2014; 67: 504-9.
84. Elnaz VM, Beitullah A, Aziz HR, Sakineh KS, Mohammad AJ, Sema Z, Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis. Nutrition 2014; 30: 430-5.
85. Calcinaro F, Dionisi S, Marinaro M, et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 2005; 48: 1565-75.
86. Andersson U, Bränning C, Ahrné S, et al. Probiotics lower plasma glucose in the high-fat fed C57BL/6J mouse. Benef Microbes 2010; 1: 189-96.
87. Yokokura T, Yajima T, Hashimoto S. Effect of organic acid on gastrointestinal motility of rat in vitro. Life Sci 1977; 21: 59-62.
88. Shukla G, Sidhu RK. Lactobacillus casei as a probiotic in malnourished Giardia lamblia-infected mice: a biochemical and histopathological study. Can J Microbiol 2011; 57: 127-35.
89. Camelia S, Floarea S, Gabriela B, Anca S. The hypercholesterolemic effect of probiotics in the hyperlipidemic hamster. Proc Rom Acad 2008; 3: 145-9.
90. Lye HS, Kuan CY, Ewe JA, Fung WY, Liong MT. The Improvement of Hypertension by Probiotics: Effects on Cholesterol, Diabetes, Renin, and Phytoestrogens. Int J Mol Sci 2009; 10: 3755-75.
91. Donkor ON, Henriksson A, Vasiljevic T, Shah NP. Probiotic strains as starter cultures improve angiotensin-converting enzyme inhibitory activity in soy yogurt. J Food Sci 2005; 70: 375-81.
92. David R. Mack, Sonia Michail, Shu Wei, Laura McDougall, Michael A. Hollingsworth. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physol-Gastrointestinal Liver Physiol 1999; 276: G941-50.
93. Goldin BR, Gorbach SL, Saxelin M, Barakat S, Gualtieri L, Salminen S. Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci 1992; 37: 121-8.
94. Chassaing B, Darfeuille MA. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterol 2011; 140: 1720-28.
95. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterol 2002; 122: 44-54.
96. Antoni L, Nuding S, Wehkamp J, Stange EF. Intestinal barrier in inflammatory bowel disease. World J Gastroenterol 2014; 20: 1165-79.
97. Nenci A, Becker C, Wullaert A et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007; 446; 7135: 557-61.
98. Patel B, Schutte R, Sporns P, et al. Potato glycoalkaloids adversely affect intestinal permeability and aggravate inflammatory bowel disease. Inflamm Bowel Dis 2002; 8: 340-6.
99. Moehle C, Ackermann N, Langmann T, et al. Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J Mol Med 2006; 84: 1055-66.
100. Gersemann M, Becker S, Kübler I, et al. Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation 2009; 77: 84-94.
101. Matricon J, Barnich N, Ardid D. Immunopathogenesis of inflammatory bowel disease. Self Nonself 2010; 1: 299-309.
102. Van der SM, De Koning BA, De Bruijn AC, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006; 131: 117-29.
103. Schulzke JD, Ploeger S, Amasheh M, et al. Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci 2009; 1165: 294-300.
104. Weber cr. Inflammatory bowel disease: is it really just another break in the wall? Gut 2007; 56: 6-8.
105. Michael S, Gerhard R. Microbial sensing by the intestinal epithelium in the pathogenesis of inflammatory bowel disease. Int J Inflamm 2010; Article ID 671258.
106. Cario E, Podolsky DK.Differential alteration in intestinal epithelial cell expression of toll like receptor 3(TLR3) and TRLR4 in inflammatory bowel disease. Infect Immun 2000; 68: 7010-17.
107. Abreu MT, Fukata M, Arditi M. TLR signalling in the gut in health and disease. J Immunol 2005; 174: 4453-60.
108. Ma TY, Iwamoto GK, Hoa NT, et al. TNF--induced increase in intestinal epithelial tight junction permeability requires NF-B activation. Am J Physiol 2004; 286: G367-76.
109. Stevens CG, Walz C, Singaram ML. et al. Tumor necrosis factor-, interleukin-1, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992; 37: 818-26.
110. Prasenjit D, Pooja G, Tapash KD, et al. Comparative tight junction protein expressions in colonic Crohn’s disease, ulcerative colitis, and tuberculosis: a new perspective. Virchows Arch 2012; 460: 261-70.
111. Goswami P, Das P, Verma AK, et al. Are alterations of tight junctions at molecular and ultrastructural level different in duodenal biopsies of patients with celiac disease and Crohn's disease? Virchows Arch 2014; 465: 521-30.
112. Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995; 270: 1203-7.
113. Vetrano S, Rescigno M, Cera MR, et al. Unique role of junctional adhesion molecule-A in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology 2008; 135: 173-84.
114. Bai AP, Q Ouyang. Probiotics and inflammatory bowel diseases. Postgrad Med J 2006; 82: 376-82.
115. Mack DR. Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999; 276: G941-G95.
116. Duary RK, Bhausaheb MA, Batish VK, Grover S. Antiinflammatory and immunomodulatory efficacy of indigenous pro biotic Lactobacillus plantarum Lp91 in colitis mouse model. Mol Biol Rep 2012; 39: 4765-75.
117. Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 2003; 52: 827-33.
118. Dulantha U, Rachel CA, Warren C.et al. Regulation of tight junction permeability by intestinal bacteria and dietary components. J. Nutr 2011; 141: 769-76.
119. Ukena SN, Singh A, Dringenberg U, et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2007; 2(12): e1308.
120. Anderson RC, Cookson AL, McNabb WC, et al. Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC Microbiol 2010; 10: 316.
121. Corridoni D, Pastorelli L, Mattioli B, et al. Probiotic bacteria regulate intestinal epithelial permeability in experimental ileitis by a TNF-dependent mechanism. PLoS One 2012; 7: e42067.
122. Zakostelska Z, Kverka M, Klimesova K, et al. Lysate of probiotic lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS One 2011; 6: e27961.
123. Riedel CU, Foata F, Philippe D, Adolfsson O, Eikmanns BJ, Blum S. Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-KB activation. World J Gastroenterol 2006; 12: 3729-35.
124. De Kivit MC, Tobin CB, Forsyth AK, Landay AL. Regulation of intestinal immune responses through TLR activation: implications for pro-and prebiotics. Front Immunol 2014; 5: 60.
125. Mann ER, Li X. Intestinal antigen-presenting cells in mucosal immune homeostasis: crosstalk between dendritic cells, macrophages and B-cells, World J Gastroenterol 2014; 20; 9653-64.
126. Kim SW, Kim HM, Yang KM, et al. Bifidobacterium lactis inhibits NF-B in intestinal epithelial cells and prevents acute colitis and colitis-associated colon cancer in mice. Inflamm Bowel Dis 2010; 16: 1514-25.
127. Molodecky NA, Kaplan GG. “Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol 2010; 6: 339-46.
128. Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53: 685-93.
129. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780-5.
130. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 2006; 55: 205-11.
131. Dalal SR, Chang EB. The microbial basis of inflammatory bowel diseases. J Clin Invest 2014; 124: 4190-6.
132. Gophna U, Sommerfeld K, Gophna S, Doolittle WF, Veldhuyzen van Zanten SJO. Differences between tissue-associated intestinal microfloras of patients with Crohn’s disease and ulcerative colitis. J Clin Microbiol 2006; 44: 4136-41.
133. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007; 449; 804-10.
134. Konstantinos Papamichael, Panagiotis Konstantopoulos, Gerassimos J Mantzaris. Helicobacter pylori infection and inflammatory bowel disease: Is there a link?. World J Gastroenterol 2014; 7: 6374-85.
135. Miranda BJ, Padilla SC, Bouza E, Muñoz P, Menchén L, Marín JI. Listeria monocytogenes infection in inflammatory bowel disease patients: case series and review of the literature. Eur J Gastroenterol Hepatol 2014; 26: 1247-52.
136. Christodoulou D, Tsianos EV. Listeria monocytogenes infection in patients with Inflammatory Bowel Disease: Is there an increased risk with immunomodulators or biologic agents? Ann Gastroenterol 2010; 23: 159-61.
137. Bassler A. The bacteriology of ulcerative colitis. Med J Rec 1933; 138: 427-428.
138. Ternhag A, Torner A, Svensson A, Ekdahl K, Giesecke J. “Shortand long-term effects of bacterial gastrointestinal infections, ” Emerging Infectious Diseases 2008; 14: 143-48.
139. Warren Strober, Adherent-invasive E. coli in crohns disease: bacterial’agent provocateur J Clin Invest 2011; 121: 841-4.
140. Pilarczyk-Zurek M, Chmielarczyk A, Gosiewski T, et al. Possible role of Escherichia coli in propagation and perpetuation of chronic inflammation in ulcerative colitis. BMC Gastroenterol 2013; 13: 61.
141. Simmonds NJ, Rampton DS: Inflammatory bowel disease a radical view. Gut 1993; 34: 865-68.
142. Ellen S Pierce. Ulcerative colitis and Crohn's disease: is Mycobacterium avium subspecies paratuberculosis the common villain? Gut Pathogens 2010; 2: 21.
143. Uzoigwe JC, Khaitsa ML, Gibbs PS: Epidemiological evidence for Mycobacterium avium subspecies paratuberculosis as a cause of Crohn's disease. Epidemiol Infect 2007; 135: 1057-68.
144. Frank DN: Mycobacterium avium subspecies paratuberculosis and Crohn's disease. Lancet Infect Dis 2008; 8: 345-46.
145. Sherris JC, Ryan KJ. Medical microbiology: an introduction to infectious diseases. New York: Elsevier 1984.
146. Spieker T, Herbst H. Distribution and phenotype of Epstein-Barr virus-infected cells in inflammatory bowel disease. Am J Pathol 2000; 157: 51-7.
147. Cadwell K, Patel KK, Maloney NS, et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell 2010; 141: 1135-45.
148. Pironi L, Bonvicini F, Gionchetti P, et al. Parvovirus b19 infection localized in the intestinal mucosa and associated with severe inflammatory bowel disease. J Clin Microbiol 2009; 47: 1591-95.
149. Montgomery SM, Morris DL, Pounder RE, Wakefield AJ. Paramyxovirus. Infections in childhood and subsequent inflammatory bowel disease. Gastroenterol 1999; 116: 796-803.
150. Garrido E, Carrera E, Manzano R, Lopez-Sanroman A. Clinical significance of cytomegalovirus infection in patients with inflammatory bowel disease. World J Gastroenterol 2013; 19: 17-25.
151. Giaffer MH, Holdsworth CD, Duerden BI. The assessment of faecal flora in patients with inflammatory bowel diseases by a simplified bacteriological technique. J Med Microbiol 1991; 35: 238-43.
152. Bocker U, Nebe T, Herweck F, et al. Butyrate modulates intestinal cell-mediated neutrophil migration. Clin Exp Immunol 2003; 131: 53-60.
153. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillusspecies prevents colitis in interleukin 10 genedeficient mice. Gastroenterology 1999; 116: 1107-14.
154. Flynn S, Van Sinderen D, Thornton GM, Holo H, Nes IF, Collins JK. Characterization of the genetic locus responsible for the production of ABP-118, a novel bacteriocin produced by the probiotic bacterium Lactobacillus salivarius subsp. salivarius UCC118, ” Microbiology 2002; 148; 973-84.
155. Miriam S, Jan W, Artur A, Tobias AO, Eduard F, Klaus F. Induction of human -defensin 2 by the probiotic Escherichia coli Nissle 1917 Is Mediated through Flagellin. Infect Immun 2007; 75: 2399-407.
156. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-23.
157. Travis SPL, Stange EF, Lemann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn’s Colitis 2008; 2: 24-62.
158. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Alim Pharmacol Therapeutics 1999; 13: 1103-8.
159. Malin M, Suolalainen H, Saxelin M, Isolauri E. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996; 40: 137-45.
160. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51; 405-9.
161. Castillo NA, de Morenode Le Blanc A, M Galdeano C, Perdigón G. Comparative study of the protective capacity against Salmonella infection between probiotic and nonprobiotic Lactobacilli. J Appl Microbiol 2013; 114: 861-76.
162. Makuuchi M, Takayama T, Kosuge T, et al. The value of ultrasonography for hepatic surgery. Hepatogastroenterol 1991; 38: 64-70.
163. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease, Am J Gastroenterol 2006; 101: 812-22.
164. Ingrassia I, Leplingard A, Darfeuille-Michaud A. Lactobacillus casei DN-114 001 inhibits the ability of Adherent-Invasive Escherichia coli isolated from Crohn’s disease patients to adhere to and to invade intestinal epithelial cells. Appl Environ Microbiol 2005; 71: 2880-7.
165. Neuman MG. Immune dysfunction in inflammatory bowel disease. Transl Res 2007; 149: 173-86.
166. Atreya R, Neurath MF.Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 2005; 28: 187-96.
167. Wang L, Walia B, Evans J, Gewirtz AT, Merlin D, Sitaraman SV. IL-6 Induces NF-B activation in the intestinal epithelia. J Immunol 2003; 171: 3194-201.
168. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
169. Allocca M, Jovani M, Fiorino G, Schreiber S, Danese S. Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. Curr Drug Targets 2013; 14(12): 1508-21.
170. Neurath MF, Finotto S, Fuss I, et al. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol 2001; 22: 21-6.
171. Bernardo D, Vallejo-Díez, S, Mann ER, et al. IL-6 promotes immune responses in human ulcerative colitis and induces a skinhoming phenotype in the dendritic cells and Tcells they stimulate. Eur J Immunol 2012; 42: 1337-53.
172. Ito H. IL-6 and Crohn's disease. Curr Drug Targets Inflamm Allergy 2003; 2: 125-30.
173. Carey R, Jurickova I, Ballard E, et al. Activation of an IL-6: STAT3-dependent Transcriptome in Pediatric-onset Inflammatory Bowel Disease. Inflamm Bowel Dis 2008; 14(4): 446-57.
174. Yamamoto M, Yoshizaki K, Kishimoto T, et al. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000; 164: 4878-82.
175. Atreya R, Mudter J, Finotoo S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn’s disease and experimental colitis in vivo. Nat Med 2000; 6: 583-8.
176. Matsumoto S, Hara T, Hori T, et al. Probiotic Lactobacillusinduced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Expl Immunol 2005; 140: 417-26.
177. Yoon H, Yoon YS, Kim MS, Chung MJ, Yum DY. A probiotic preparation duolac-gold ameliorates dextran sulphate sodiuminduced mouse colitis by downregulating the expression of IL-6. Toxicol Res 2014; 30: 27-32.
178. Hegazy SK, El-Bedewy MM. Effect of probiotics on proinflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol 2010; 16: 4145-51.
179. Li-Xuan S, Bing C, Cong D, Nan G, Wei-Xin L, Min J. Heat-killed VSL#3 ameliorates dextran sulfate sodium (DSS)-induced acute experimental colitis in rats. Int J Mol Sci 2014; 15: 15-28.
180. Carol M, Borruel N, Antolin M, et al. Modulation of apoptosis in intestinal lymphocytes by a probiotic bacteria in Crohn's disease. J Leukocyte Biol 2006; 79: 917-22.
181. Schultz M, Strauch UG, Linde H-J, et al. Preventive effects of Escherichia coli Strain nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol 2004; 11(2): 372-78.
182. Fergus Shanahan. Probiotics in inflammatory bowel disease— therapeutic rationale and role. Adv Drug Deliv Rev 2004; 56: 809-18.
183. Sanders ME, Akkermans LM, Haller D, et al. Safety assessment of probiotics for human use. Gut Microbes 2010; 1: 164-85.
184. Yousef N, Babak H, Norhafizah A, et al. Probiotics or antibiotics: future challenges in medicine. J Med Microbiol 2015; 64: 137-46